Page last updated: 2024-08-21

quinazolines and funiculosin (anthraquinone)

quinazolines has been researched along with funiculosin (anthraquinone) in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chang, GC; Chen, HW; Chen, JJ; Chen, MH; Lai, YH; Lin, SY; Wong, YH; Yang, CH; Yu, SL	1

Other Studies

1 other study(ies) available for quinazolines and funiculosin (anthraquinone)

Article	Year
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways. Oncotarget, 2015, Sep-22, Volume: 6, Issue:28 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Computer-Aided Design; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Mice, SCID; Molecular Docking Simulation; Molecular Structure; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases; Structure-Activity Relationship; Time Factors; Xenograft Model Antitumor Assays	2015

Article

Year

Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.

Oncotarget, 2015, Sep-22, Volume: 6, Issue:28

Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Computer-Aided Design; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Mice, SCID; Molecular Docking Simulation; Molecular Structure; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases; Structure-Activity Relationship; Time Factors; Xenograft Model Antitumor Assays

2015